Diadexus, Inc. Share Price

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/21/17	Diadexus, Inc. Went Out of Business	CI
08/18/08	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2T 42.9T 40.4T 36.79T 68.99T 47.13L 69.07T 5L 2L 24.01L 2L 2L 77.48L	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	52.9L 46.13L 43.44L 39.56L 74.18L 51Cr 74.27L 5.2Cr 2.01Cr 26Cr 1.99Cr 1.94Cr 83Cr	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/21/17	Diadexus, Inc. Went Out of Business	CI
08/18/08	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/18/09	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/16/01	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/16/29	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/16/29	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/16/20	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/16/07	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/16/07	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/16/13	Diadexus, Inc. Filed for Bankruptcy	CI
10/16/10	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/16/23	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/16/30	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
SAREPTA THERAPEUTICS, INC.	+3.92%	+1.54%	+12.82%	-82.46%	212.73Cr
ULTRAGENYX PHARMACEUTICAL INC.	+7.30%	+19.55%	-46.98%	-57.11%	143.99Cr
BIONOTE, INC.	+0.43%	-1.89%	-24.80%	-2.40%	34Cr
DK LIFE SCIENCE CO., LTD.	+29.98%	+37.95%	-30.07%	-	5.43Cr
Average	+8.32%	+6.89%	-22.26%	-47.32%	79.26Cr
Weighted average by Cap.	+5.18%	+1.13%	-12.74%	-66.13%

	2014	2015
Net sales	2.61Cr 2.28Cr 2.14Cr 1.95Cr 3.66Cr 250.16Cr 3.67Cr 26Cr 9.9Cr 127.43Cr 9.81Cr 9.59Cr 411.21Cr	1.79Cr 1.56Cr 1.47Cr 1.34Cr 2.51Cr 171.33Cr 2.51Cr 18Cr 6.78Cr 87Cr 6.72Cr 6.57Cr 281.64Cr
Net income	-84.67L -73.82L -69.53L -63.32L -1.19Cr -81Cr -1.19Cr -8.33Cr -3.21Cr -41Cr -3.18Cr -3.11Cr -133.34Cr	-71.66L -62.48L -58.85L -53.59L -1Cr -69Cr -1.01Cr -7.05Cr -2.72Cr -35Cr -2.69Cr -2.63Cr -112.85Cr
Net Debt	-2L -2L -2L -1L -3L -1.9Cr -3L -19.47L -8L -96.63L -7L -7L -3.12Cr	52.41L 45.7L 43.04L 39.19L 73.49L 50Cr 73.58L 5.15Cr 1.99Cr 26Cr 1.97Cr 1.93Cr 83Cr

Diadexus, Inc. Share Price

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news: Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile